19 Jul 21 | Shanghai Henlius Biotech announced that the first patient has been dosed in its Ph I clinical trial of...
Pearce IP BioBlast®: w/e 23 July 2021
read more
Home / News / Pearce IP Blog
ALL BLOGS BY
Naomi Pearce
Naomi is listed in IAM Patent 1000 as one of Australia's leading patent litigators. Underpinning Naomi’s legal work is a deep understanding of the pharma/biopharma industries, resulting from first hand experience and knowledge as VP of IP in-house at global pharma giants, and Partner of a top-tier international law firm.
See Naomi's full profile
Blockchain technology gets a nod as patentable subject matter
Advanced New Technologies Co., Ltd. [2021] APO 29
Date: 21 July 2021Forum: Australian Patent OfficeDelegate: Ranganath Subbarayan Background Australian Patent...
Pearce IP BioBlast®: w/e 16 July 2021
12 Jul 21 | Boditech Med announced it has obtained export approval for AFIAS Adalimumab, a diagnostic kit which...
Pearce IP BioBlast®: w/e 09 July 2021
05 Jul 21 | Chong Kun Dang announced it has signed a commercialisation agreement with Menagen for Nesbell® (biosimilar...
Let the applicant beware!
Misrepresentations are not just limited to examples
Although Australia has taken steps in recent years to harmonise its patent laws with those around the globe,...
Pearce IP BioBlast®: w/e 02 July 2021
27 Jun 21 | CN | Innovent Biologics announced China’s National Medical Products Administration has approved its...
Sisters are doin’ it for themselves: female inventors more likely to invent for women
A new report demonstrates that female-dominated inventor teams in biomedical sciences are more likely to invent...
Words matter – Specification guides claim construction
Caffitaly System S.P.A. v One Collective Group Pty Ltd [2021] FCAFC 118
Date: 30 June 2021Court: Full Court of the Federal Court of AustraliaJudges: Yates, Moshinsky and Burley JJ Background...
Pearce IP BioBlast®: w/e 25 June 2021
23 Jun 21 | US | Genentech announced that the FDA has accepted the BLA for its Port Delivery System with ranibizumab...
Diagnostic tests that rely on a naturally occurring phenomenon patent eligible in Australia
Diagnostic tests that rely on a naturally occurring phenomenon patent eligible in Australia On 18 June 2021, the Full...
Correspondence lost to spam filter justifies extension of time
QIP Nominees Pty Ltd v Delinia, Inc. [2021] APO 24
Date: 22 June 2021Forum: Australian Patent OfficeDelegate: Xavier Gisz Background As part of the Raising the Bar...
Pearce IP BioBlast®: w/e 18 June 2021
10 June 21 | The UK's NICE published final draft guidance recommending adalimumab, etanercept and infliximab for the...
Pearce IP BioBlast®: w/e 11 June 2021
07 Jun 21 | Celltrion launched Remsima SC® (subcutaneous infliximab biosimilar) in Canada. Remsima SC® is indicated...
Common sense prevails in new interpretation of pharmaceutical extension of terms
Ono Pharmaceutical Co, Ltd v Commissioner of Patents [2021] FCA 643
Date: 11 June 2021Court: Federal Court of AustraliaJudge: Beach J Background Under Australian law, patents that cover...
Sticking the knife in – owner of scalpel removal device patent survives entitlement attack
Michael Sinnott v Aunex Pty Ltd [2021] APO 23
Date: 08 June 2021 Forum: Australian Patent Office Delegate: Felix White Background This case concerned a dispute as...
Pearce IP BioBlast®: w/e 04 June 2021
31 May 21 | Celltrion will launch Yuflyma® (biosimilar adalimumab) in the EU in June, as reported by the Korea Herald....